JPRN-jRCT1040220009已完成未知
Clinical study on allergic factors in patients with osteoarthritis of the knee and hips who have been treated with SI-613/ONO-5704 - CONCEPTIO
ishida Yoshihiro0 个研究点目标入组 27 人开始时间: 2022年4月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
In BAT, reagents containing DEH showed a significant association between positive/negative and Case/Control, suggesting that the characteristics of DEH may be involved in the anaphylactic symptoms after SI-613/ONO-5704 injection. In addition, DF IgE were detected in four (positive in BAT) of the 13 Cases by specific IgE antibody test (ELISA), suggesting the possibility that DF IgE is involved in the onset of anaphylaxis after injection.BAT and ELISA were found to be useful for investigating causal factors.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients with osteoarthritis of the knee or hip who have received one or more JOYCLU intra-articular injection.
- •2. Patients who fall under any of the following.
- •a. Experienced anaphylaxis (including allergy).
- •Patients who have a history of anaphylactic (including serious allergies) symptoms that are considered to be associated with JOYCLU intra-articular injection after administration of JOYCLU intra-articular injection. Anaphylaxis (including serious allergies) was judged by a physician who performed the medical treatment based on the presence or absence of systemic symptoms such as the patient's skin, digestive organs, respiratory organs, circulatory organs, and neurological symptoms, or the need for urgent treatment and hospitalization.
- •b. No experiences of allergic symptoms.
- •Patients who do not have a history of allergic symptoms that are considered to be related to JOYCLU intra-articular injection after receiving JOYCLU intra-articular injection.
- •3. Male or female aged 20 years or older at the time of signing the informed consent.
- •4. Patients who give voluntary written informed consent to participate in the study after receiving and understanding the adequate explanation about the study.
排除标准
- •1. Patients who have a history of anaphylaxis (including serious allergies) within 2 weeks prior to informed consent.
- •2. Patients who are considered ineligible by the principal investigator or sub-investigator.
研究者
相似试验
撤回
3 期
Efficacy and Safety of the Association Drugs in Patients With Allergic DermatitisDermatitisNCT01125761Azidus Brasil
已完成
不适用
A Study on the association with allergen, a stimulant and skin condition of babies.Healthy babysJPRN-UMIN000038153Kao Corporation40
已完成
不适用
Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic PatientsAtopic DermatitisAsthmaAllergic RhinitisConjunctivitisNCT04984941Second Affiliated Hospital, School of Medicine, Zhejiang University100
已完成
4 期
A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch TestsHealthyPsoriasisAtopic DermatitisNCT03406117Haus Bioceuticals182
Unknown
不适用
PF and FeNO and Clinical Characteristics in Children Being Diagnosed Due to Suspicion of Allergic DiseasesHealthyAtopic DermatitisAsthmaAllergic RhinitisUrticariaNCT01805635Medical University of Lodz5,500